Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera(®) was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors. Using the concept of PRRT, Lutathera(®) combine...

Descripción completa

Detalles Bibliográficos
Autores principales: Hennrich, Ute, Kopka, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789871/
https://www.ncbi.nlm.nih.gov/pubmed/31362406
http://dx.doi.org/10.3390/ph12030114
_version_ 1783458713138364416
author Hennrich, Ute
Kopka, Klaus
author_facet Hennrich, Ute
Kopka, Klaus
author_sort Hennrich, Ute
collection PubMed
description As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera(®) was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors. Using the concept of PRRT, Lutathera(®) combines the radionuclide (177)Lu with the somatostatin analogue DOTA-TATE, thus delivering ionizing radiation specifically to tumor cells expressing somatostatin receptors. As a result, DNA single- and double-strand breaks are provoked, in case of double-strand breaks leading to cell death of the tumor and its SSTR-positive lesions.
format Online
Article
Text
id pubmed-6789871
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67898712019-10-16 Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy Hennrich, Ute Kopka, Klaus Pharmaceuticals (Basel) Review As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera(®) was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors. Using the concept of PRRT, Lutathera(®) combines the radionuclide (177)Lu with the somatostatin analogue DOTA-TATE, thus delivering ionizing radiation specifically to tumor cells expressing somatostatin receptors. As a result, DNA single- and double-strand breaks are provoked, in case of double-strand breaks leading to cell death of the tumor and its SSTR-positive lesions. MDPI 2019-07-29 /pmc/articles/PMC6789871/ /pubmed/31362406 http://dx.doi.org/10.3390/ph12030114 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hennrich, Ute
Kopka, Klaus
Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
title Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
title_full Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
title_fullStr Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
title_full_unstemmed Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
title_short Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
title_sort lutathera(®): the first fda- and ema-approved radiopharmaceutical for peptide receptor radionuclide therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789871/
https://www.ncbi.nlm.nih.gov/pubmed/31362406
http://dx.doi.org/10.3390/ph12030114
work_keys_str_mv AT hennrichute lutatherathefirstfdaandemaapprovedradiopharmaceuticalforpeptidereceptorradionuclidetherapy
AT kopkaklaus lutatherathefirstfdaandemaapprovedradiopharmaceuticalforpeptidereceptorradionuclidetherapy

Ejemplares similares